General information
Offer title : Development and characterization of first-in-class therapeutic antibodies (M/F) (H/F)
Reference : UMR7275-GERLAM-003
Number of position : 1
Workplace : VALBONNE
Date of publication : 22 August 2025
Type of Contract : Researcher in FTC
Contract Period : 24 months
Expected date of employment : 1 October 2025
Proportion of work : Full Time
Remuneration : Between 3,021 and 4,664 euros gross per month, depending on experience
Desired level of education : Doctorate
Experience required : 1 to 4 years
Section(s) CN : 28 - Pharmacology, bio-engineering, imaging, biotechnology
Missions
The agent will independently be in charge of the production of anti-PLA2 antibodies for therapeutic applications, from immunization steps to molecular characterization, in vitro and in vivo.
Activities
- To produce different antigens (PLA2) in recombinant form with cutting-edge methods.
- To implement methods for immunisation and production of monoclonal antibodies and nanobodies against the different PLA2 antigens.
- To characterize the molecular and functional properties of antibodies, in vitro and in vivo in mice.
- To format results, interpretation, validation.
Skills
- Extensive experience in molecular and cellular biology, protein engineering, recombinant production in prokaryotic and eukaryotic systems, ideally for antibodies
- Ability to work independently and as part of a team
- Good organizational skills
- Demonstrated attention to details
Skills:
- In-depth knowledge of molecular biology, biochemistry, cell biology, and immunology techniques is essential.
- Ability to use IT tools and software dedicated to data processing and results presentation.
Work Context
The recruitment of the agent is open as part of a program funded by the ANR and internal resources. The agent will work in the team “Molecular Physiopathology of Phospholipases A2 and Their Mediators”, under the direct supervision of the team leader. The team consists of approximately 10 people working on PLA2 and its receptor PLA2R1, which are involved in various inflammatory and autoimmune diseases and constitute therapeutic targets, particularly as immune checkpoint candidates.
The IPMC is a multidisciplinary institute with approximately 250 people comprising more than 20 research teams.
The agent will be trained in the potential risks associated with the project by the manager upon arrival at the laboratory. The agent will also receive training for new entrants provided by the biological and chemical risk prevention assistants.
The position is located in a sector under the protection of scientific and technical potential (PPST), and therefore requires, in accordance with the regulations, that your arrival is authorized by the competent authority of the MESR.
Constraints and risks
Risks associated with biological agents, chemicals, and screen use.
Additional Information
none